

# A phase 1/2 trial of arginine butyrate and ganciclovir in virus-associated lymphoid malignancies

Blood

109, 2571-2578

DOI: [10.1182/blood-2006-01-024703](https://doi.org/10.1182/blood-2006-01-024703)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epstein-Barr Virus and Hodgkin Lymphoma. Hematology American Society of Hematology Education Program, 2007, 2007, 204-209.	0.9	54
2	Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells, Molecules, and Diseases, 2007, 38, 57-65.	0.6	21
3	Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 1265-1269.	0.7	7
5	Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. Journal of Medical Virology, 2008, 80, 879-882.	2.5	28
6	Immunodeficiency-associated lymphomas. Blood Reviews, 2008, 22, 261-281.	2.8	149
7	Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nature Medicine, 2008, 14, 1118-1122.	15.2	85
8	Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells. Virus Research, 2008, 135, 175-180.	1.1	7
9	Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leukemia and Lymphoma, 2008, 49, 27-34.	0.6	124
10	Clinical and Virological Characteristics of Patients with Chronic Active Epstein-Barr Virus Infection Treated with Hematopoietic Stem Cell Transplantation: Insights and Questions. Clinical Infectious Diseases, 2008, 46, 1535-1536.	2.9	2
11	Imaging Virus-Associated Cancer. Current Pharmaceutical Design, 2008, 14, 3048-3065.	0.9	3
12	Histone Deacetylase Inhibitors: New Hope for Rheumatoid Arthritis?. Current Pharmaceutical Design, 2008, 14, 803-820.	0.9	59
14	Drug Targets in Herpes Simplex and Epstein Barr Virus Infections. Infectious Disorders - Drug Targets, 2009, 9, 117-125.	0.4	17
15	How I treat EBV lymphoproliferation. Blood, 2009, 114, 4002-4008.	0.6	287
16	Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 323-336.	1.4	2
17	Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments. Virus Genes, 2009, 38, 195-203.	0.7	11
18	Tax unleashed: Fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation. Journal of Clinical Virology, 2009, 46, 378-380.	1.6	1
19	Treatment advances in posttransplant lymphoproliferative disease. Current Opinion in Hematology, 2010, 17, 368-374.	1.2	41
20	Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma. Journal of Immunotherapy, 2010, 33, 983-990.	1.2	201

#	ARTICLE	IF	CITATIONS
21	Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy. <i>Current Oncology Reports</i> , 2010, 12, 383-394.	1.8	133
22	Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation. <i>Metabolomics</i> , 2010, 6, 229-237.	1.4	32
23	Posttransplant Lymphoproliferative Disorder Following Kidney Transplant. <i>American Journal of Kidney Diseases</i> , 2010, 55, 168-180.	2.1	28
24	Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. <i>British Journal of Haematology</i> , 2010, 149, 693-705.	1.2	191
25	Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e169-74.	0.7	26
26	Butyric acid in bowel inflammations. <i>Przegląd Gastroenterologiczny</i> , 2010, 5, 251-257.	0.3	2
27	The Epstein-Barr Virus (EBV)-Encoded Protein Kinase, EBV-PK, but Not the Thymidine Kinase (EBV-TK), Is Required for Ganciclovir and Acyclovir Inhibition of Lytic Viral Production. <i>Journal of Virology</i> , 2010, 84, 4534-4542.	1.5	131
28	Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1113-1127.	1.9	12
29	Risk stratification in extranodal natural killer/T-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1395-1405.	1.1	7
30	Upregulation of STAT3 Marks Burkitt Lymphoma Cells Refractory to Epstein-Barr Virus Lytic Cycle Induction by HDAC Inhibitors. <i>Journal of Virology</i> , 2010, 84, 993-1004.	1.5	46
31	Viral Response to Chemotherapy in Endemic Burkitt Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 2055-2064.	3.2	22
32	Immunotherapy against EBV-lymphoma in recipients of HSCT. <i>Expert Review of Hematology</i> , 2010, 3, 625-632.	1.0	6
33	Diagnosis and management of natural killer-cell malignancies. <i>Expert Review of Hematology</i> , 2010, 3, 593-602.	1.0	31
34	Epstein-Barr virus as a prognostic factor in non-nodal diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 66-72.	0.6	47
35	Posttransplant Lymphoproliferative Diseases. <i>Pediatric Clinics of North America</i> , 2010, 57, 481-503.	0.9	49
36	Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. <i>Human Pathology</i> , 2010, 41, 352-357.	1.1	115
37	The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. <i>Cancer Treatment Reviews</i> , 2010, 36, 348-353.	3.4	37
39	Post-transplant lymphoproliferative disorders following solid-organ transplantation. <i>Expert Review of Hematology</i> , 2010, 3, 35-44.	1.0	31

#	ARTICLE	IF	CITATIONS
40	Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Posttransplant Lymphoproliferative Disorder. <i>Clinical Microbiology Reviews</i> , 2010, 23, 350-366.	5.7	201
41	Role of CD4 <sup>+</sup> Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer. <i>International Reviews of Immunology</i> , 2010, 29, 371-402.	1.5	47
42	Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far. <i>Oncologist</i> , 2011, 16, 87-96.	1.9	99
43	EBV-Positive Diffuse Large B-Cell Lymphoma in Young Immunocompetent Individuals. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 512-516.	0.2	56
45	Posttransplant Lymphoproliferative Disorders Following Kidney Transplantation. , 2011, , .		0
46	Monitoraggio e gestione delle infezioni virali in riceventi pediatrici di trapianto renale. <i>Giornale De Tecniche Nefrologiche &amp; Dialitiche</i> , 2011, 23, 38-44.	0.1	0
47	Extranodal natural killer/T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2011, 23, 429-435.	1.1	28
48	Bortezomib induction of C/EBP $\beta$ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma. <i>Blood</i> , 2011, 117, 6297-6303.	0.6	72
49	Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy. <i>American Journal of Transplantation</i> , 2011, 11, 888-895.	2.6	117
50	Lymphoproliferative Disorders After Solid Organ Transplantation- Classification, Incidence, Risk Factors, Early Detection and Treatment Options. <i>Pathology and Oncology Research</i> , 2011, 17, 443-454.	0.9	79
51	The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 67-72.	1.2	9
52	Newly Emerging Therapies Targeting Viral-Related Lymphomas. <i>Current Oncology Reports</i> , 2011, 13, 416-426.	1.8	21
53	Antiglioma effects of combined use of a baculoviral vector expressing wild-type p53 and sodium butyrate. <i>Journal of Gene Medicine</i> , 2011, 13, 26-36.	1.4	11
54	EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru. <i>American Journal of Hematology</i> , 2011, 86, 663-667.	2.0	65
55	Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update. <i>Leukemia and Lymphoma</i> , 2011, 52, 950-961.	0.6	23
56	Therapeutic options in post-transplant lymphoproliferative disorders. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 393-407.	1.1	27
57	Valproic Acid Antagonizes the Capacity of Other Histone Deacetylase Inhibitors To Activate the Epstein-Barr Virus Lytic Cycle. <i>Journal of Virology</i> , 2011, 85, 5628-5643.	1.5	42
58	The Impact of Gut Microbiota in Human Health and Diseases: Implication for Therapeutic Potential. <i>Biomolecules and Therapeutics</i> , 2011, 19, 155-173.	1.1	5

#	ARTICLE	IF	CITATIONS
59	Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-19.	3.3	31
60	An Epstein-Barr Virus (EBV) Mutant with Enhanced BZLF1 Expression Causes Lymphomas with Abortive Lytic EBV Infection in a Humanized Mouse Model. <i>Journal of Virology</i> , 2012, 86, 7976-7987.	1.5	102
61	Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma. <i>Molecular Medicine Reports</i> , 2012, 6, 477-482.	1.1	22
62	Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. <i>Blood</i> , 2012, 119, 1008-1017.	0.6	131
63	Butyrate Histone Deacetylase Inhibitors. <i>BioResearch Open Access</i> , 2012, 1, 192-198.	2.6	138
64	Managing Post-Transplant Lymphoproliferative Disorders in Solid-Organ Transplant Recipients. <i>Drugs</i> , 2012, 72, 1631-1643.	4.9	34
65	Post-transplant lymphoproliferative disorders. <i>Diagnostic Histopathology</i> , 2012, 18, 281-289.	0.2	3
66	Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. <i>Advances in Virology</i> , 2012, 2012, 1-11.	0.5	49
67	Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations. <i>Current Treatment Options in Oncology</i> , 2012, 13, 122-136.	1.3	145
68	Monitoring and managing viral infections in pediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 2012, 27, 705-717.	0.9	33
70	Non-Hodgkin Lymphoma. , 2013, , .		1
71	Pediatric Cancer, Volume 4. <i>Pediatric Cancer</i> , 2013, , .	0.0	0
72	Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells. <i>Life Sciences</i> , 2013, 93, 509-515.	2.0	36
73	EBV-Related Lymphomas: New Approaches to Treatment. <i>Current Treatment Options in Oncology</i> , 2013, 14, 224-236.	1.3	70
74	Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 173-183.	1.2	253
75	Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2013, 6, 94.	6.9	67
76	Epstein-Barr Virus-Induced CD30-Positive Diffuse Large B-Cell Lymphoma in a Patient With Mixed-Phenotypic Leukemia Treated With Clofarabine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 342-346.	0.2	5
77	Phase I Clinical Trial of Valacyclovir and Standard of Care Cyclophosphamide in Children With Endemic Burkitt Lymphoma in Malawi. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 112-118.	0.2	5

#	ARTICLE	IF	CITATIONS
78	Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disorder. <i>American Journal of Transplantation</i> , 2013, 13, 41-54.	2.6	252
79	Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 107-120.	2.6	140
80	Epstein-Barr infection: Current treatment options. <i>Annals of Tropical Medicine and Public Health</i> , 2013, 6, 10.	0.1	3
81	hTERT Inhibition Triggers Epstein-Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. <i>Clinical Cancer Research</i> , 2013, 19, 2036-2047.	3.2	27
82	Les lymphomes cutanés. , 2013, , .		0
83	Signal Transducer and Activator of Transcription 3 Limits Epstein-Barr Virus Lytic Activation in B Lymphocytes. <i>Journal of Virology</i> , 2013, 87, 11438-11446.	1.5	42
84	A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQB-1001), an oral fetal globin inducer, in sickle cell disease. <i>American Journal of Hematology</i> , 2013, 88, E255-60.	2.0	31
85	EBV-positive diffuse large B-cell lymphoma of the elderly. <i>Blood</i> , 2013, 122, 328-340.	0.6	203
86	Molecular Pathogenesis of B-Cell Posttransplant Lymphoproliferative Disorder: What Do We Know So Far?. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-13.	3.3	80
87	Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	87
88	The pathology of lung transplantation. , 0, , 767-803.		0
89	Activation and Repression of Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycles by Short- and Medium-Chain Fatty Acids. <i>Journal of Virology</i> , 2014, 88, 8028-8044.	1.5	54
90	Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models. <i>FASEB Journal</i> , 2014, 28, 2603-2619.	0.2	15
91	Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 786-794.	0.6	16
92	Switching of EBV cycles between latent and lytic states. <i>Reviews in Medical Virology</i> , 2014, 24, 142-153.	3.9	122
93	Regulation of Epstein-Barr virus reactivation from latency. <i>Microbiology and Immunology</i> , 2014, 58, 307-317.	0.7	102
94	Anti-Viral Treatment and Cancer Control. <i>Recent Results in Cancer Research</i> , 2014, 193, 269-290.	1.8	10
95	Identification of a New Class of Small Molecules That Efficiently Reactivate Latent Epstein-Barr Virus. <i>ACS Chemical Biology</i> , 2014, 9, 785-795.	1.6	27

#	ARTICLE	IF	CITATIONS
96	Oncologic Issues and Kidney Transplantation: A Review of Frequency, Mortality, and Screening. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 106-113.	0.6	38
97	Regulation of the latent-lytic switch in Epstein-Barr virus. <i>Seminars in Cancer Biology</i> , 2014, 26, 60-68.	4.3	219
98	Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion. <i>Medical Oncology</i> , 2014, 31, 800.	1.2	14
100	Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. <i>British Journal of Haematology</i> , 2014, 165, 300-315.	1.2	24
101	Viruses and Human Cancer. <i>Recent Results in Cancer Research</i> , 2014, , .	1.8	1
102	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 673-691.	21.5	1,277
103	Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 891-915.	2.5	5
104	Validation of NCM460 cell model as control in antitumor strategies targeting colon adenocarcinoma metabolic reprogramming: Trichostatin A as a case study. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 1634-1639.	1.1	12
106	Bioprotective Carnitinoïds: Lipoic Acid, Butyrate, and Mitochondria-Targeting to Treat Radiation Injury: Mitochondrial Drugs Come of Age. <i>Drug Development Research</i> , 2015, 76, 167-175.	1.4	13
107	Post-transplant lymphoproliferative disease and other malignancies after pediatric cardiac transplantation. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 562-569.	0.8	10
108	Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies. <i>PLoS ONE</i> , 2015, 10, e0145994.	1.1	18
109	Post-transplant Lymphoproliferative Disorders. <i>Cancer Treatment and Research</i> , 2015, 165, 305-327.	0.2	73
110	Cellular STAT3 Functions via PCBP2 To Restrain Epstein-Barr Virus Lytic Activation in B Lymphocytes. <i>Journal of Virology</i> , 2015, 89, 5002-5011.	1.5	33
112	Icaritin induces lytic cytotoxicity in extranodal NK/T-cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 17.	3.5	32
113	Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1845-1857.	1.2	47
114	The biology and treatment of plasmablastic lymphoma. <i>Blood</i> , 2015, 125, 2323-2330.	0.6	355
115	Epstein-Barr Virus Lytic Cycle Reactivation. <i>Current Topics in Microbiology and Immunology</i> , 2015, 391, 237-261.	0.7	70
116	Infection-associated non-Hodgkin lymphomas. <i>Clinical Microbiology and Infection</i> , 2015, 21, 991-997.	2.8	22

#	ARTICLE	IF	CITATIONS
117	Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. <i>Experimental and Molecular Medicine</i> , 2015, 47, e134-e134.	3.2	62
118	The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 456-467.	1.2	60
119	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. <i>Cell Death and Disease</i> , 2015, 6, e1774-e1774.	2.7	28
120	Adoptive T-Cell Immunotherapy. <i>Current Topics in Microbiology and Immunology</i> , 2015, 391, 427-454.	0.7	48
121	Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment. <i>Cancer Letters</i> , 2015, 369, 37-44.	3.2	118
122	Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. <i>Experimental and Molecular Medicine</i> , 2015, 47, e136-e136.	3.2	56
123	Inhibition of autophagy in EBV-positive Burkitt's lymphoma cells enhances EBV lytic genes expression and replication. <i>Cell Death and Disease</i> , 2015, 6, e1876-e1876.	2.7	43
124	Review: Biological and Pharmacological Basis of Cytolytic Viral Activation in EBV-Associated Nasopharyngeal Carcinoma. , 2016, , .		2
125	Agents and Approaches for Lytic Induction Therapy of Epstein-Barr Virus Associated Malignancies. , 2016, 6, .		2
126	Plasmablastic Lymphoma Mimicking Acute Pancreatitis. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-4.	0.2	5
127	Histone Deacetylase Inhibitors Increase p27 <sup>Kip1</sup> by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-17.	1.9	9
128	Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. <i>Haematologica</i> , 2016, 101, 803-811.	1.7	273
129	Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. <i>Drug Development Research</i> , 2016, 77, 53-72.	1.4	30
130	Prise en charge thérapeutique des infections à herpès virus : traitements actuels et futurs. <i>Revue Francophone Des Laboratoires</i> , 2016, 2016, 55-64.	0.0	0
131	Murine Models of Epstein-Barr Virus-Associated Lymphomagenesis. <i>ILAR Journal</i> , 2016, 57, 55-62.	1.8	13
132	Post-transplant Lymphoproliferative Disorder (PTLD): Infection, Cancer?. <i>Current Transplantation Reports</i> , 2016, 3, 145-153.	0.9	0
133	Trichloromethane fraction of <i>Incarvillea compacta</i> induces lytic cytotoxicity and apoptosis in Epstein-Barr virus-positive gastric cancer AGS cells. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 344.	3.7	8
134	Epstein-Barr Virus Infection and Lymphoproliferative Disorders After Transplantation. , 2016, , 477-512.		2



#	ARTICLE	IF	CITATIONS
135	EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 529-537.	2.0	74
136	Primary Intestinal Hodgkin Lymphoma Mimicking Intraabdominal Abscess in a Renal Transplant Recipient: A Case Report. <i>Oncology Research and Treatment</i> , 2016, 39, 817-821.	0.8	0
137	Oncogenic $\beta$ Herpesviruses EBV and HHV8 in Kidney Transplantation. <i>Seminars in Nephrology</i> , 2016, 36, 362-371.	0.6	6
138	Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 411-421.	1.1	14
139	Therapeutics Targeting Protein Acetylation Perturb Latency of Human Viruses. <i>ACS Chemical Biology</i> , 2016, 11, 669-680.	1.6	8
140	Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. <i>Annals of Oncology</i> , 2016, 27, 508-513.	0.6	51
142	Practical Nutrition Guidelines for Individuals with Duchenne Muscular Dystrophy. <i>Pancreatic Islet Biology</i> , 2016, , 225-279.	0.1	1
143	Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study. <i>Clinical Transplantation</i> , 2017, 31, e12983.	0.8	18
144	A major turning point in NK/T-cell lymphoma?. <i>Blood</i> , 2017, 129, 2342-2343.	0.6	9
145	Managing post-transplant lymphoproliferative disorder. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 19-35.	0.5	9
146	Epstein-Barr virus and renal transplantation. <i>Transplantation Reviews</i> , 2017, 31, 55-60.	1.2	39
147	Epstein-Barr virus lymphoproliferative disease after solid organ transplantation. <i>Cytotherapy</i> , 2017, 19, 1270-1283.	0.3	12
148	Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Clinics in Chest Medicine</i> , 2017, 38, 771-783.	0.8	14
149	Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF- $\kappa$ B/miR-155/PU.1 pathway. <i>BMC Cancer</i> , 2017, 17, 147.	1.1	17
150	Epigenetic Treatment of Persistent Viral Infections. <i>Drug Development Research</i> , 2017, 78, 24-36.	1.4	17
151	Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 133.	3.5	14
152	Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2018, 50, 2154-2158.	0.3	4
153	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. <i>Clinical Cancer Research</i> , 2018, 24, 3273-3281.	3.2	20

#	ARTICLE	IF	CITATIONS
154	How I treat T-cell chronic active Epstein-Barr virus disease. <i>Blood</i> , 2018, 131, 2899-2905.	0.6	72
155	Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1341-1349.	2.0	26
156	Plasmablastic lymphoma: current perspectives. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2018, Volume 8, 63-70.	1.2	75
157	EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression. <i>Pathology</i> , 2018, 50, 725-729.	0.3	12
158	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2018, 93, 953-962.	2.0	75
159	Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications. <i>Infectious Agents and Cancer</i> , 2018, 13, 14.	1.2	4
160	Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production. <i>Journal of Virology</i> , 2019, 93, .	1.5	9
161	Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disease. , 2019, , 643-666.		0
162	The Tumor Microenvironment in Post-Transplant Lymphoproliferative Disorders. <i>Cancer Microenvironment</i> , 2019, 12, 3-16.	3.1	20
163	Development of a novel inducer for EBV lytic therapy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2259-2264.	1.0	7
164	Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13652.	0.8	206
165	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease. , 2019, , 195-211.		1
166	Untargeted metabolomics analysis of the upper respiratory tract of ferrets following influenza A virus infection and oseltamivir treatment. <i>Metabolomics</i> , 2019, 15, 33.	1.4	20
167	Control of viral infections by epigenetic-targeted therapy. <i>Clinical Epigenetics</i> , 2019, 11, 55.	1.8	67
168	Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders. <i>Frontiers in Oncology</i> , 2019, 9, 127.	1.3	31
169	Management of post-transplant lymphoproliferative disorders. <i>HemaSphere</i> , 2019, 3, 74-77.	1.2	1
170	Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals. <i>Frontiers in Oncology</i> , 2020, 10, 1723.	1.3	34
171	Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. <i>Microorganisms</i> , 2020, 8, 1824.	1.6	63

#	ARTICLE	IF	CITATIONS
172	Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation. <i>MBio</i> , 2020, 11, .	1.8	17
173	Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas. <i>Cancers</i> , 2020, 12, 2565.	1.7	25
174	The Crosstalk of Epigenetics and Metabolism in Herpesvirus Infection. <i>Viruses</i> , 2020, 12, 1377.	1.5	14
175	Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. <i>Frontiers in Oncology</i> , 2020, 10, 506.	1.3	21
176	Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. <i>Blood</i> , 2020, 135, 1870-1881.	0.6	39
177	Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2020, 9, 865.	1.0	6
178	A Brief Review of Nutraceutical Ingredients in Gastrointestinal Disorders: Evidence and Suggestions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1822.	1.8	31
179	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 435-445.	2.0	35
180	Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 545-558.	1.5	9
181	Management of PTLD after SOT. , 2021, , 167-190.		1
182	Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorders. , 2021, , 655-682.		0
183	Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment. , 2021, 4, 646-664.		4
184	Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 865-878.	0.8	6
185	An immune epigenetic insight to COVID-19 infection. <i>Epigenomics</i> , 2021, 13, 465-480.	1.0	32
186	Frontline management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2021, 193, 727-740.	1.2	16
187	The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis. <i>Frontiers in Pharmacology</i> , 2021, 12, 625543.	1.6	10
188	Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies. <i>Expert Review of Hematology</i> , 2021, 14, 731-740.	1.0	2
189	Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review. <i>American Journal of Kidney Diseases</i> , 2021, 78, 272-281.	2.1	29

#	ARTICLE	IF	CITATIONS
190	EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. <i>Blood</i> , 2022, 139, 983-994.	0.6	17
191	Post-transplant Lymphoproliferative Disease. , 2021, , 265-276.		0
192	Management of PTLD After HSCT. , 2021, , 221-237.		0
193	The Epstein-Barr Virus Lytic Life Cycle. , 2009, , 285-315.		6
194	Posttransplant Lymphoproliferative Disease (PTLD) in Hematopoietic Stem Cell Transplantation (HSCT). , 2010, , 173-182.		2
195	Treatment of PTLD. , 2010, , 117-131.		1
196	EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly. , 2012, , 83-98.		1
197	Pediatric Leukemia of Natural Killer Cells: Diagnosis and Multi-Agent Chemotherapy. <i>Pediatric Cancer</i> , 2013, , 139-151.	0.0	1
198	Introduction to Herpesviridae. , 2010, , 1937-1942.		3
199	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
200	Herpesvirus latency. <i>Journal of Clinical Investigation</i> , 2020, 130, 3361-3369.	3.9	127
201	Productively Infected Murine Kaposi's Sarcoma-Like Tumors Define New Animal Models for Studying and Targeting KSHV Oncogenesis and Replication. <i>PLoS ONE</i> , 2014, 9, e87324.	1.1	13
202	Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. <i>Oncotarget</i> , 2015, 6, 31018-31029.	0.8	23
203	EBV reactivation as a target of luteolin to repress NPC tumorigenesis. <i>Oncotarget</i> , 2016, 7, 18999-19017.	0.8	31
204	EBV-Associated Malignancies. <i>The Open Infectious Diseases Journal</i> , 2010, 4, 101-112.	0.6	3
205	Posttransplant lymphoproliferative disorders following liver transplantation: <i>Where are we now?</i> . <i>World Journal of Gastroenterology</i> , 2015, 21, 11034.	1.4	16
206	EBV in Hodgkin Lymphoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009013.	0.5	40
207	Non-Hodgkin lymphoma after pediatric kidney transplantation. <i>Pediatric Nephrology</i> , 2022, 37, 1759-1773.	0.9	4

#	ARTICLE	IF	CITATIONS
208	T-cell Therapy for the Treatment of Epstein Barr Virus-Associated Malignancies. Immunotherapy Insights, 0, , 3.	0.0	2
209	Post-transplant Lymphoproliferative Disorder. , 2010, , 597-618.		0
210	The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV), Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662 Td (		0
211	Molecular Targeting of Post-transplant Lymphoproliferative Disorders. , 2010, , 215-228.		0
212	Posttransplant Lymphoproliferative Disorders Following Solid Organ Transplantation. , 0, , .		0
213	Epstein-Barr Virus Lymphomagenesis and Therapeutic Targets. , 2013, , 47-61.		0
214	LymphoprolifÃ©rations post-transplantation dâ€™organe solide. , 2013, , 225-235.		0
215	Posttransplant Lymphomas. , 2013, , 267-277.		0
216	Malignancies After Transplantation and Posttransplant Lymphoproliferative Disorder. , 2014, , 269-280.		0
217	Introduction to Herpesviridae. , 2015, , 1707-1712.e1.		1
218	Cancer in the Kidney Transplant Recipient. , 2015, , 319-350.		0
220	Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Effective Platinum-Based Salvage Chemotherapy for Periportal Posttransplant Lymphoproliferative Disorder After an Orthotopic Liver Transplant. Experimental and Clinical Transplantation, 2015, 13, 475-8.	0.2	0
221	Viral Infections in Organ Transplant Recipients. , 0, , 75-98.		0
222	Posttransplant Lymphoproliferative Disorders in Bone Marrow. , 2018, , 890-895.		0
223	Monitoraggio e gestione delle infezioni virali in riceventi pediatriche di trapianto renale. Giornale Di Clinica Nefrologica E Dialisi, 2011, 23, 38-44.	0.0	0
224	Posttransplant Lymphoproliferative Disorders. , 2018, , 824-829.		0
225	Aggressive Lymphoma in Children and Adolescents. Mechanical Engineering Series, 2019, , 245-282.	0.1	0
226	A case of idiopathic inflammatory myopathy complicated by Epstein-Barr virus-associated lymphoma. Hong Kong Bulletin on Rheumatic Diseases, 2018, 18, 72-76.	0.1	0

#	ARTICLE	IF	CITATIONS
227	Sensitizing Burkitt lymphoma to EBV-CTLs. <i>Blood</i> , 2020, 135, 1822-1823.	0.6	7
228	Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorders. , 2020, , 1-29.		2
230	Clinical and Therapeutic Implications of Epstein-Barr Virus in HIV-Related Lymphomas. <i>Cancers</i> , 2021, 13, 5534.	1.7	15
231	Chapter XX Antiviral Treatment and Cancer Control. <i>Recent Results in Cancer Research</i> , 2021, 217, 325-354.	1.8	0
235	How Does Epstein-Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 852066.	1.8	8
236	Epigenetic modifying potential of Lipoic acid: Implications in curing diabetes. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 6747-6752.	0.2	0
237	Relapsed Plasmablastic Lymphoma in an HIV-Infected Patient-Experience of High-Dose Chemotherapy with Autologous Stem Cell Rescue: A Case Report with Review of Literature. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
238	Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment. <i>Current Opinion in Oncology</i> , 2022, 34, 413-421.	1.1	4
239	Clinical Post-Transplant Lymphoproliferative Disorders. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2022, 22, 96-103.	0.2	1
240	Therapeutic approaches to Epstein-Barr virus cancers. <i>Current Opinion in Virology</i> , 2022, 56, 101260.	2.6	7
241	EBV-associated diseases: Current therapeutics and emerging technologies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
242	Lactate drives cellular DNA repair capacity: Role of lactate and related short-chain fatty acids in cervical cancer chemoresistance and viral infection. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
243	Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder. <i>Cancers</i> , 2022, 14, 5949.	1.7	6
244	Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101446.	0.7	6
245	Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. <i>Nature Reviews Neurology</i> , 2023, 19, 160-171.	4.9	48
246	Drugs That Mimic Hypoxia Selectively Target EBV-Positive Gastric Cancer Cells. <i>Cancers</i> , 2023, 15, 1846.	1.7	0
247	Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies. <i>British Journal of Haematology</i> , 2023, 201, 383-395.	1.2	10
253	Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1

#	ARTICLE	IF	CITATIONS
254	Perspicive Chapter: Modulation of Latent to Lytic Cycle Infection Switch and its Implication in EBV Mediated Tumorigenicity. , 0, , .		0
259	Nutraceuticals and phytoceuticals in the treatment of colon disorders. , 2024, , 223-241.		0